Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/32703 |
Resumo: | Botulinum toxin (BT) presents itself as a less invasive alternative for the correction of strabismus, acting by the high affinity for cholinergic synapses, which causes a blockage of acetylcholine release. Such application, consequently, causes a lower chemical-neural receptivity, reducing muscle responsiveness to contracture, not causing, however, complete paralysis. Through this mechanism, the injection of botulinum toxin type A (TBA) into the extraocular muscles allows the alteration of ocular alignment creating a temporary paralysis, producing an overcorrection of the strabismus in which a shortening of the antagonist muscle is induced. Histologically, a change in sarcomere density may occur, which favors permanent ocular alignment. In a partial analysis, several authors report good results with the use of TBA in the treatment of different presentations of strabismus. There are several classifications of indication, expected effects, and adverse effects through the procedure, which must be considered upon patient admission. Thus, botulinum toxin, injected intramuscularly, binds to terminal receptors found in motor nerves, acting by blocking the release of acetylcholine in the presynaptic terminal, deactivating fusion proteins, which prevents the release of acetylcholine in the synaptic cleft, which does not allow depolarization of the postsynaptic terminal, blocking muscle contraction by temporary chemical denervation. |
id |
UNIFEI_c3bff47cec72b93427ee227398414e90 |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/32703 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature reviewEvaluación del uso de la toxina botulínica tipo A para la regresión del estrabismo: una revisión sistemática de la literaturaAvaliação do uso da toxina botulínica do tipo A para regressão de estrabismo: uma revisão sistemática de literaturaEstrabismoToxina botulínica tipo AAcetilcolina.StrabismusBotulinum toxin type AAcetylcholine.EstrabismoToxina botulínica tipo AAcetilcolina. Botulinum toxin (BT) presents itself as a less invasive alternative for the correction of strabismus, acting by the high affinity for cholinergic synapses, which causes a blockage of acetylcholine release. Such application, consequently, causes a lower chemical-neural receptivity, reducing muscle responsiveness to contracture, not causing, however, complete paralysis. Through this mechanism, the injection of botulinum toxin type A (TBA) into the extraocular muscles allows the alteration of ocular alignment creating a temporary paralysis, producing an overcorrection of the strabismus in which a shortening of the antagonist muscle is induced. Histologically, a change in sarcomere density may occur, which favors permanent ocular alignment. In a partial analysis, several authors report good results with the use of TBA in the treatment of different presentations of strabismus. There are several classifications of indication, expected effects, and adverse effects through the procedure, which must be considered upon patient admission. Thus, botulinum toxin, injected intramuscularly, binds to terminal receptors found in motor nerves, acting by blocking the release of acetylcholine in the presynaptic terminal, deactivating fusion proteins, which prevents the release of acetylcholine in the synaptic cleft, which does not allow depolarization of the postsynaptic terminal, blocking muscle contraction by temporary chemical denervation.La toxina botulínica (BT) se presenta como una alternativa menos invasiva para la corrección del estrabismo, actuando por la alta afinidad por las sinapsis colinérgicas, lo que provoca un bloqueo de la liberación de acetilcolina. Tal aplicación, en consecuencia, provoca una menor receptividad químico-neuronal, reduciendo la respuesta muscular a la contractura, sin causar, sin embargo, una parálisis completa. Mediante este mecanismo, la inyección de toxina botulínica tipo A (TBA) en los músculos extraoculares permite alterar la alineación ocular creando una parálisis temporal, produciéndose una sobrecorrección del estrabismo en la que se induce un acortamiento del músculo antagonista. Histológicamente puede ocurrir un cambio en la densidad de los sarcómeros, lo que favorece la alineación ocular permanente. En un análisis parcial, varios autores reportan buenos resultados con el uso de TBA en el tratamiento de diferentes presentaciones de estrabismo. Existen varias clasificaciones de indicación, efectos esperados y efectos adversos a través del procedimiento, los cuales deben ser considerados al ingreso del paciente. Así, la toxina botulínica, inyectada por vía intramuscular, se une a los receptores terminales que se encuentran en los nervios motores, actuando bloqueando la liberación de acetilcolina en la terminal presináptica, desactivando las proteínas de fusión, lo que impide la liberación de acetilcolina en la hendidura sináptica, lo que no permite la despolarización. de la terminal postsináptica, bloqueando la contracción muscular por denervación química temporal.A toxina botulínica (TB) se apresenta como uma alternativa menos invasiva para correção do estrabismo, agindo pela alta afinidade por sinapses colinérgicas, o que ocasiona um bloqueio de liberação de acetilcolina. Tal aplicação, consequentemente, provoca uma menor receptividade químico-neural, reduzindo a responsividade muscular à contratura, não ocasionando, entretanto, paralisia completa. Mediante esse mecanismo, a injeção de toxina botulínica do tipo A (TBA) nos músculos extraoculares permite a alteração do alinhamento ocular criando uma paralisia temporária, produzindo uma sobrecorreção do estrabismo na qual um encurtamento do músculo antagonista é induzido. Histologicamente, pode ocorrer uma mudança na densidade dos sarcômeros, o que favorece o alinhamento ocular permanente. Em análise parcial, vários autores relatam bons resultados com o uso da TBA no tratamento de diversas apresentações do estrabismo. Existem diversas classificações de indicação, efeitos esperados e efeitos adversos mediante o procedimento, que devem ser considerados na admissão do paciente. Assim, a toxina botulínica, injetada por via intramuscular, liga-se aos receptores terminais encontrados nos nervos motores, agindo pelo bloqueio da liberação de acetilcolina no terminal pré-sináptico, desativando proteínas de fusão, o que impede o lançamento de acetilcolina na fenda sináptica, o que não permite a despolarização do terminal pós-sináptico, bloqueando a contração da musculatura por denervação química temporária.Research, Society and Development2022-07-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3270310.33448/rsd-v11i10.32703Research, Society and Development; Vol. 11 No. 10; e244111032703Research, Society and Development; Vol. 11 Núm. 10; e244111032703Research, Society and Development; v. 11 n. 10; e2441110327032525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/32703/27732Copyright (c) 2022 Júlia Fernandes Nogueira; Bárbara Queiroz de Figueiredo; Daniel Henrique Mendes Batista; Fernanda Oliveira Pinto; Maria Jacilene de Araújo Gomes; Isadora Queiroz Presot; Ítalo Gomes Farias; Sarah Grace Alves Travassohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessNogueira, Júlia FernandesFigueiredo, Bárbara Queiroz de Batista, Daniel Henrique MendesPinto, Fernanda OliveiraGomes, Maria Jacilene de AraújoPresot, Isadora QueirozFarias, Ítalo GomesTravasso, Sarah Grace Alves2022-08-12T22:23:03Zoai:ojs.pkp.sfu.ca:article/32703Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:36.688192Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review Evaluación del uso de la toxina botulínica tipo A para la regresión del estrabismo: una revisión sistemática de la literatura Avaliação do uso da toxina botulínica do tipo A para regressão de estrabismo: uma revisão sistemática de literatura |
title |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
spellingShingle |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review Nogueira, Júlia Fernandes Estrabismo Toxina botulínica tipo A Acetilcolina. Strabismus Botulinum toxin type A Acetylcholine. Estrabismo Toxina botulínica tipo A Acetilcolina. |
title_short |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
title_full |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
title_fullStr |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
title_full_unstemmed |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
title_sort |
Evaluation of the use of botulinum toxin type A for strabismus regression: a systematic literature review |
author |
Nogueira, Júlia Fernandes |
author_facet |
Nogueira, Júlia Fernandes Figueiredo, Bárbara Queiroz de Batista, Daniel Henrique Mendes Pinto, Fernanda Oliveira Gomes, Maria Jacilene de Araújo Presot, Isadora Queiroz Farias, Ítalo Gomes Travasso, Sarah Grace Alves |
author_role |
author |
author2 |
Figueiredo, Bárbara Queiroz de Batista, Daniel Henrique Mendes Pinto, Fernanda Oliveira Gomes, Maria Jacilene de Araújo Presot, Isadora Queiroz Farias, Ítalo Gomes Travasso, Sarah Grace Alves |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Nogueira, Júlia Fernandes Figueiredo, Bárbara Queiroz de Batista, Daniel Henrique Mendes Pinto, Fernanda Oliveira Gomes, Maria Jacilene de Araújo Presot, Isadora Queiroz Farias, Ítalo Gomes Travasso, Sarah Grace Alves |
dc.subject.por.fl_str_mv |
Estrabismo Toxina botulínica tipo A Acetilcolina. Strabismus Botulinum toxin type A Acetylcholine. Estrabismo Toxina botulínica tipo A Acetilcolina. |
topic |
Estrabismo Toxina botulínica tipo A Acetilcolina. Strabismus Botulinum toxin type A Acetylcholine. Estrabismo Toxina botulínica tipo A Acetilcolina. |
description |
Botulinum toxin (BT) presents itself as a less invasive alternative for the correction of strabismus, acting by the high affinity for cholinergic synapses, which causes a blockage of acetylcholine release. Such application, consequently, causes a lower chemical-neural receptivity, reducing muscle responsiveness to contracture, not causing, however, complete paralysis. Through this mechanism, the injection of botulinum toxin type A (TBA) into the extraocular muscles allows the alteration of ocular alignment creating a temporary paralysis, producing an overcorrection of the strabismus in which a shortening of the antagonist muscle is induced. Histologically, a change in sarcomere density may occur, which favors permanent ocular alignment. In a partial analysis, several authors report good results with the use of TBA in the treatment of different presentations of strabismus. There are several classifications of indication, expected effects, and adverse effects through the procedure, which must be considered upon patient admission. Thus, botulinum toxin, injected intramuscularly, binds to terminal receptors found in motor nerves, acting by blocking the release of acetylcholine in the presynaptic terminal, deactivating fusion proteins, which prevents the release of acetylcholine in the synaptic cleft, which does not allow depolarization of the postsynaptic terminal, blocking muscle contraction by temporary chemical denervation. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-07-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/32703 10.33448/rsd-v11i10.32703 |
url |
https://rsdjournal.org/index.php/rsd/article/view/32703 |
identifier_str_mv |
10.33448/rsd-v11i10.32703 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/32703/27732 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 10; e244111032703 Research, Society and Development; Vol. 11 Núm. 10; e244111032703 Research, Society and Development; v. 11 n. 10; e244111032703 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052719035318272 |